OKYO Pharma Ltd. Form 6-K Summary
Filing date: May 19, 2022. This Form 6-K was furnished by OKYO Pharma Ltd., a foreign private issuer, under Form 20-F reporting status. The filing relates to a news service announcement regarding the closing of an offering.
Business Context and Reporting Period
The filing does not contain operating or period-end financial statements. It reports that the company issued a U.S. news service announcement titled “Closing of Offering” on May 19, 2022. The announcement was furnished as Exhibit 99.1, but its substantive text is not included in the provided filing content.
Financial Metrics and Capitalization
- Revenue, profit, cash flow, margins, debt, liquidity, offering size, securities issued, pricing, and use of proceeds are not clearly provided in the filing text.
- The filing therefore does not permit assessment of the company’s financial performance or post-offering capitalization.
Material Changes Versus Prior Period
No comparable-period financial information or quantified changes are provided. The only reported event is the closing of an offering.
Guidance, Outlook, Risks, and Unusual Items
- No management guidance, operating outlook, risk discussion, contingencies, or unusual accounting items are included in the provided text.
- The offering announcement may contain material financing terms and risks, but those details are not available in the supplied filing content.
- Exhibit 99.1 is expressly furnished rather than filed for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference except as expressly specified.
Key Facts for Investor Verification
- Obtain and review Exhibit 99.1 to verify the offering’s size, security type, issue price, closing conditions, and gross and net proceeds.
- Confirm the intended use of proceeds and any impact on shares outstanding, dilution, warrants, or other securities.
- Review subsequent filings for the company’s cash balance, liquidity runway, financing obligations, and updated capitalization.